Antibiotic Development Is Economically Broken — New Antibiotics Must Be Used Sparingly to Work

Unlike other drugs, new antibiotics are deliberately used sparingly to prevent resistance, which destroys the economic incentive to develop them. Multiple antibiotic startups have gone bankrupt despite FDA approval. The PASTEUR Act proposes $6B in subscription-style payments to fix this, but hasn't passed yet.

More than 2.8M drug-resistant infections occur in the US annually, causing 35,000 deaths. The PASTEUR Act (reintroduced 2026) would create subscription-style contracts: fixed annual payments of $75M-$300M per drug, delinked from sales volume. Achaogen (plazomicin) went bankrupt in 2019 despite FDA approval. Melinta Therapeutics filed for bankruptcy. The pipeline has thinned dramatically — only 43 antibiotics are in clinical development globally (vs. ~1,300 cancer drugs).

Why It Matters

AMR could kill 10M people/year by 2050 (O'Neill Review). WHO lists AMR as a top 10 global health threat. Current antibiotic market: ~$55B/year, but almost entirely generics. Japan developing revenue guarantee program; EU supporting AMR partnerships.

Startup Approach

Develop novel antibiotic classes using AI-driven discovery (e.g., halicin discovered by ML). Or build a platform for rapid antibiotic susceptibility testing that guides optimal existing antibiotic use, reducing resistance emergence. Position for PASTEUR Act subscription contracts if passed.

NIH Funding

NIAID funds antibiotic resistance research extensively. BARDA funds CARB-X accelerator. ARPA-H has expressed interest in antimicrobial innovation.

Who's Working On It

PASTEUR Act sponsors (bipartisan, $6B proposed), GARDP (Global Antibiotic R&D Partnership), CARB-X (BARDA-funded accelerator), Entasis Therapeutics, Shionogi (subscription model pioneer)